Valtech, cardioband, transcatheter mitral annuloplasty

September 2, 2015 — HeartWare International Inc. announced it entered into a definitive agreement to acquire Valtech Cardio Ltd.  Valtech is a privately held company that specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for the treatment of the most prevalent heart valve diseases – mitral valve regurgitation (MR) and tricuspid valve regurgitation (TR).
acute ischemic stroke, larger thrombi retrieval, improved neurological recovery, ESC 2015, MR CLEAN trial, sub-study

Retrieval of larger thrombi during intra-arterial treatment (IAT) is associated with improved neurological recovery after acute ischemic stroke, according to a sub-study of the MR CLEAN trial.
DOPPLER-CIP trial, ESC 2015, heart failure, predictor, small left ventricle, University of Leuven

Findings presented at the European Society of Cardiology (ESC) Congress 2015 indicate that a small left ventricle with thick walls is the strongest predictor of morphologic remodeling in chronic ischemic heart disease patients.

Emergency department patients with chest pain suggestive of acute myocardial infarction (AMI) can be triaged more quickly and safely using a new rapid assay with refined cut-offs, German research suggests.

Medtronic, OPTILINK, OptiVol, ICD, pulmonary congestion, ESC 2015

Automated alerts for excess fluid accumulation in the lungs did not improve outcomes for heart failure patients with implantable cardioverter defibrillators (ICDs), according to results of the OPTILINK HF trial.

The first-ever two-year outcomes from the Global Anticoagulant Registry in the Field - Atrial Fibrillation (GARFIELD-AF) were showcased at the European Society of Cardiology (ESC) Congress 2015 in London.

Based on its recent analysis of the cardiovascular image management market, Frost & Sullivan recognizes Pie Medical Imaging (PMI) with the 2015 European Frost & Sullivan Award for Technology Leadership.

September 1, 2015 — A bioresorbable drug-eluting coronary stent showed similar efficacy and safety results compared to a metal stent in patients undergoing percutaneous coronary intervention (PCI), according to results of the ABSORB Japan study.

The findings, reported in a Hot Line session at the European Society of Cardiology (ESC) 2015 congress.

bivalirudin,angiomax

September 1, 2015 — Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the procedure, according to results from the MATRIX Treatment Duration trial.

Medtronic plc announced first-of-its-kind findings from two independent studies that have identified a gene associated with life-threatening abnormal heart rhythms. The study results were presented in a hotline session at the 2015 European Society of Cardiology (ESC) Congress in London.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now